Sentinel lymph node biopsy for melanoma: an important risk-stratification tool

David E Gyorki and Michael A Henderson
Med J Aust 2015; 202 (2): . || doi: 10.5694/mja14.01610
Published online: 2 February 2015

In reply: We thank Zagarella and colleagues for their comments and the opportunity to correct some misconceptions about the Multicenter Selective Lymphadenectomy Trial-1 study.1

  • David E Gyorki
  • Michael A Henderson

  • Peter MacCallum Cancer Centre, Melbourne, VIC.


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.